menu
    • menu

    Company profile for Soligenix

    NEW Drugs in Dev: 12
    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    Arlanda is your partner for the Brazil market.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Soligenix has specialized knowledge in the development of orphan and unmet medical need indications including preclinical, manufacturing, regulatory and clinical expertise. We are a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need. Soligenix has a number of Public Health programs, funded entirely by government grants and contra...
    Soligenix has specialized knowledge in the development of orphan and unmet medical need indications including preclinical, manufacturing, regulatory and clinical expertise. We are a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need. Soligenix has a number of Public Health programs, funded entirely by government grants and contracts, which focus on infectious disease and biodefense applications, including our most advanced vaccination program to prevent ricin poisoning.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SoligenixUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    29 Emmons Drive Suite B-10 Princeton, NJ 08540
    Telephone
    Telephone
    609-538-8200
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.soligenix.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/soligenix-inc-/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/Soligenix_Inc

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    PBP World Meeting

    Not Confirmed

    envelop Contact Supplier

    PBP World Meeting

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Soligenix Announces HyBryte Clinical Summary Published
    Soligenix Announces HyBryte Clinical Summary Published

    19 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-announces-hybryte-clinical-summary-published-in-expert-opinion-on-investigational-drugs-302718249.html

    PR NEWSWIRE
    19 Mar 2026
    Share Share
    Soligenix Gains MHRA PIM Designation for SGX945
    Soligenix Gains MHRA PIM Designation for SGX945

    10 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-announces-sgx945-receives-promising-innovative-medicine-designation-from-the-uk-medicines-and-healthcare-products-regulatory-agency-302709102.html

    PR NEWSWIRE
    10 Mar 2026
    Share Share
    Soligenix SGX945 Gets EMA Orphan Designation for Behçet's Disease
    Soligenix SGX945 Gets EMA Orphan Designation for Behçet's Disease

    26 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-receives-positive-opinion-from-the-european-medicines-agency-on-the-request-for-orphan-drug-designation-for-sgx945-for-the-treatment-of-behcets-disease-302698032.html

    PR NEWSWIRE
    26 Feb 2026
    Share Share
    Soligenix Details Recent Progress And Upcoming Milestones
    Soligenix Details Recent Progress And Upcoming Milestones

    12 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-details-recent-progress-and-upcoming-milestones-302686179.html

    PR NEWSWIRE
    12 Feb 2026
    Share Share
    SGX945 Phase 2 Trial Shows Promising Results In Behçet's Disease
    SGX945 Phase 2 Trial Shows Promising Results In Behçet's Disease

    18 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/positive-clinical-results-from-phase-2-trial-of-sgx945-for-the-treatment-of-behcets-disease-published-in-rheumatology-oxford-302645452.html

    PR NEWSWIRE
    18 Dec 2025
    Share Share
    Soligenix Announces Top-line Results of the Ph 2a Study of SGX302
    Soligenix Announces Top-line Results of the Ph 2a Study of SGX302

    17 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-announces-top-line-results-of-the-phase-2a-study-of-sgx302-synthetic-hypericin-in-patients-with-mild-to-moderate-psoriasis-302644314.html

    PR NEWSWIRE
    17 Dec 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search